Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Icosavax, Inc. (ICVX : NSDQ)

• Company Description    Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company's virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $7.41 Daily Weekly Monthly 20 Day Moving Average: 181,659 shares Shares Outstanding: 39.73 (millions) Market Capitalization: $294.40 (millions) Beta: 52 Week High: $49.99 52 Week Low: $4.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.69% -16.38% 12 Week -56.51% -52.82% Year To Date -67.61% -61.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1616 EASTLAKE AVE E SUITE 208 - SEATTLE,WA 98102 USA ph: 206-737-0085 fax: - ir@icosavax.com http://icosavax.com

• General Corporate Information    Officers Adam Simpson - Chief Executive Officer and Director Mark McDade - Chairman Thomas Russo - Chief Financial Officer Elisha P. Gould - Director Peter Kolchinsky - Director Peer Information Icosavax, Inc. (CORR.) Icosavax, Inc. (RSPI) Icosavax, Inc. (CGXP) Icosavax, Inc. (BGEN) Icosavax, Inc. (GTBP) Icosavax, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45114M109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/12/22 Share - Related Items Shares Outstanding: 39.73 Most Recent Split Date: (:1) Beta: Market Capitalization: $294.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.04 Price/Cash Flow: - Price / Sales: 46.12 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -30.43% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -71.88% ROE 03/31/22 - -47.79 12/31/21 - - 09/30/21 - - ROA 03/31/22 - -35.91 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - 31.02 09/30/21 - 36.67 Quick Ratio 03/31/22 - - 12/31/21 - 31.02 09/30/21 - 36.67 Operating Margin 03/31/22 - -1,326.23 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - -1,326.23 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -858.38 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 7.13 09/30/21 - 7.42 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©